<DOC>
	<DOC>NCT01142869</DOC>
	<brief_summary>The aim of this prospective, observational, multicenter, post-marketing study is to evaluate the safety and efficacy of Cetuximab (Erbitux) in combination with platinum based chemotherapy, in the first line therapy of recurrent/ metastatic squamous cell carcinoma of head and neck (SCCHN). A total of 100 subjects with SCCHN will be recruited in 20 centres across India.</brief_summary>
	<brief_title>An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>The study inclusion criteria is as per the label for patients with metastatic/recurrent SCCHN approved by India Health Authorities, i.e., "Cetuximab is indicated for the treatment of patients with squamous cell cancer of the head and neck in combination with platinumbased chemotherapy for recurrent and/or metastatic disease." For each platinumbased chemotherapy, the related product labels approved by India Health Authorities will also be followed strictly in terms of patient eligibility. Patients with known severe (grade 3 or 4; National Cancer InstituteCommon Toxicity Criteria [NCICTC]) hypersensitivity reactions to Cetuximab are contraindicated for Cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Carcinoma, Squamous Cell</keyword>
	<keyword>Erbitux</keyword>
	<keyword>Neoplasms, Squamous Cell</keyword>
</DOC>